drugset
drugset / Trial / NCT07508761

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

NCT07508761 ↗

Phase 1/2 Recruiting 52 enrolled Nanjing Immunophage Biotech Co., Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Timeline

Start
2026-06-16
Primary completion
2028-12-30
Completion
2029-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IPG7236 Unknown 500 mg Oral
Subject IPG7236 Unknown 800 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

neoplasm